Board of Directors

Chair of the Board

John M. Dineen has served as the independent Chair of the Board of Syneos Health since December 2018. Mr. Dineen brings to the role more than 30 years of healthcare, technology and international management experience, most recently serving as Chief Executive Officer of GE’s Healthcare business from 2008 to 2014. Previously, Mr. Dineen spent more than two decades in a variety of other global leadership positions within GE, including President and Chief Executive Officer of GE Transportation, President of GE Plastics, General Manager of GE’s Power Equipment business, and General Manager of GE’s Appliances, Microwave and Air-Conditioning businesses.

Mr. Dineen currently serves on the Board of Directors of Cognizant Technology Solutions Corporation (Nasdaq:CTSH), a leading provider of information technology, consulting, and business process services, where he serves as Chair of the Finance and Strategy Committee and as a member of the Audit Committee. He also currently serves as the chair of the boards of directors of Healogics and Carestream Dental. Mr. Dineen received Bachelor’s degrees in Biology and Computer Science from the University of Vermont where he now serves on the board of trustees.

Director

Barbara W. Bodem is an independent director who joined our Board in January 2022 and is Chair of the Audit Committee. Ms. Bodem served as Interim CFO of Dentsply Sirona, Inc. (Nasdaq: XRAY), a manufacturer of professional dental products and technologies, from May 2022 until September 2022. Ms. Bodem previously served as the Senior Vice President and Chief Financial Officer at Hillrom, a global medical technology company, from 2018 until its acquisition by Baxter International Inc. (NYSE: BAX) in 2021 and as the Senior Vice President of Finance at Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She has also served in senior finance roles for Hospira, Inc. and Eli Lilly & Company (NYSE: LLY).

Ms. Bodem currently serves on the board of directors of Enovis Corporation (NYSE: ENOV), a specialty medical technology business where she serves as a member of the Audit Committee. She received both her Bachelor of Science in Finance and MBA from Indiana University.

Financial Expert; Chair of the Audit Committee

Director

Bernadette Connaughton is an independent director who joined our board in November 2019 and is a member of the Audit Committee. She has three decades of experience in global strategic and leadership roles within large pharma. Ms. Connaughton spent her career at Bristol-Myers Squibb (NYSE: BMY), building a consistent track record of achieving sales growth and improving operational models and profitability in the U.S., Europe and Asia. She most recently served as President Intercontinental. In this role, she developed successful, multi-year commercialization strategies for several oncology, virology and immunology products.

Ms. Connaughton currently serves on the Board of Directors of Zealand Pharma A/S (Nasdaq:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, where she serves on the Audit Committee and Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biotechnology company focused on novel biological and drug delivery approaches, where she serves as Chair of the Compensation Committee. She also currently serves on the Board of Directors of Editas Medicine (Nasdaq: EDIT), a gene editing company focused on developing CRISPR medicines, where she serves as Chair of the Organization, Leadership and Compensation Committee and as a member of the Nominating and Corporate Governance Committee. Ms. Connaughton serves on the Board of Trustees of the Boys and Girls Club of Mercer County, New Jersey. She was previously a member of the Board of Directors of Visterra, Inc. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.

Member of the Compensation and Management Development Committee

Member of the Audit Committee

Chief Executive Officer and Director

Ms. Keefe brings more than 30 years of life science expertise to her role as Chief Executive Officer. She joined Syneos Health in 2017, serving as President of Medical Affairs and Commercial Solutions for more than four years, overseeing multi-disciplinary teams including Medical Affairs, Real World Evidence, Full-Service Commercial, Deployment Solutions, Communications and Consulting. During this time, her work across the product development continuum included launching Kinetic™, Syneos Health’s modern customer engagement capability, building integrated solutions such as Full-Service Commercial and Medical Affairs, and collaborating to drive growth in Syneos One, the Company’s unique end-to-end offering.

Prior to Syneos Health, Ms. Keefe served as Global Group President and Chief Development Officer of Publicis Health, responsible for the Contract Sales Organization (CSO), medical affairs and specialty agency functions. Earlier in her career, she spent 20 years at Pfizer (NYSE: PFE), with increasing levels of responsibility culminating as a Regional President, and led market development for the Visiting Nurse Service of NY.

She currently serves as executive sponsor of the Syneos Health DE&I Council and is a Director at Large on the Healthcare Businesswomen’s Associations (HBA) Global Board of Directors. Ms. Keefe also serves on the Board of Directors of Execu-Search, a leading recruitment, contract staffing, and workforce solutions firm and on the Advisory Board of Humanax Acquisition Corp., a special purpose acquisition company.

Ms. Keefe holds a B.S. in marketing from Seton Hall University and completed coursework at Wharton Aresty Institute of Executive Education and PDI Ninth House General Management Assessment Center 2012 (now Korn Ferry).

Director

Mr. Klitgaard served as an Operating Executive at Avista Capital Partners, a private equity firm focused on healthcare from 2020 to 2021. He previously served as the President of Enlighten Health, a division of LabCorp (NYSE: LH) from 2015 to 2016. He also served in various roles over his 19-year career at Covance, including three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer.

Mr. Klitgaard currently serves on the board of directors of XIFIN, Inc., a health information technology company. He received his Bachelor of Arts in Economics from the University of California at Berkeley, and his Master’s of Science from the Sloan Management School at the Massachusetts Institute of Technology.

Member of the Audit Committee

Director

Mr. Klitgaard served as an Operating Executive at Avista Capital Partners, a private equity firm focused on healthcare from 2020 to 2021. He previously served as the President of Enlighten Health, a division of LabCorp (NYSE: LH) from 2015 to 2016. He also served in various roles over his 19-year career at Covance, including three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer.

Mr. Klitgaard currently serves on the board of directors of XIFIN, Inc., a health information technology company. He received his Bachelor of Arts in Economics from the University of California at Berkeley, and his Master’s of Science from the Sloan Management School at the Massachusetts Institute of Technology.

Member of the Audit Committee

Director

Kenneth F. Meyers is an independent director who joined our Board in October 2016 and is the Chair of the Compensation and Management Development Committee and a member of the Nominating and Corporate Governance Committee. Mr. Meyers currently serves as President at Ken Meyers Associates LLC, an executive coaching firm he founded in 2021. He previously served as Advisor to the Chief Executive Officer at Hillrom (NYSE:HRC), a global medical technology company, from 2020 to 2021, and as Senior Vice President and Chief Human Resources Officer at Hillrom from 2015 to 2020. Prior to that, he served as Senior Vice President and Chief Human Resources Officer at Hospira, Inc., a manufacturer and distributor of generic injectable pharmaceuticals, biosimilars and medical devices, from 2008 until its acquisition by Pfizer, Inc. in 2015. From 2004 to 2008, Mr. Meyers was a partner with Mercer/Oliver Wyman, a consulting firm specializing in leadership development. He also has served in senior human resources roles for Starbucks Coffee International, The Gymboree Corporation, Walt Disney Imagineering and United Technologies Corporation.

Mr. Meyers serves on the board of directors and the Nominating and Corporate Governance Committee for Elyssa’s Mission, a community-based non-profit organization dedicated to preventing teen suicide. He also is a member of the board of directors and Chair of the Compensation Committee for The Henry P. Kendall Foundation, an organization working to create healthy and sustainable food systems in New England, and a member of the board of directors of The Norfolk Charitable Foundation. Mr. Meyers holds a Bachelor’s degree with dual majors in International Business and Human Resource Management from the Wharton School of the University of Pennsylvania, and an MBA from the Harvard Business School.

Chair of the Compensation and Management Development Committee

Member of the Nominating and Corporate Governance Committee

Director

Matthew E. Monaghan is an independent director who joined our Board in October 2016 and serves as Chair of the Nominating and Corporate Governance Committee and is a member of the Audit Committee. Mr. Monaghan served as President, Chief Executive Officer and Chair of the Board at Invacare Corporation (NYSE:IVC), a medical device manufacturer for the home and long-term healthcare markets, for more than seven years from 2015 until August 2022. He previously served as Senior Vice President and General Manager, Global Hips and Reconstructive Research for Zimmer Biomet Holdings, Inc. (formerly known as Zimmer Holdings, Inc.) (NYSE:ZBH), a global company that designs, develops, manufactures and markets orthopedic reconstructive, spinal and trauma devices, dental implants, and related surgical products from 2014 to 2015. Mr. Monaghan also has served as Operating Executive for Texas Pacific Group from 2006 to 2009 and at Cerberus Capital Management from 2003 to 2005. He started his career with 13 years in the aerospace, medical and other industrial businesses of General Electric.

Mr. Monaghan served on the board of directors of Invacare Corporation from 2015 to 2022. He was a trustee of Cleveland Clinic Avon Lake Hospital from 2016 to 2021. Mr. Monaghan was a member of the board of directors of CD Diagnostics, Inc. from 2012 to 2016 and served as the chairman of the Audit Committee from 2012 to 2015 and as chairman of the board from 2015 to 2016. He holds a Bachelor’s degree in Mechanical Engineering from Cornell University, a Master’s degree in Mechanical Engineering from MIT and an MBA from INSEAD Business School in France.

Member of the Audit Committee

Chair of the Nominating and Corporate Governance Committee

Director

David S. Wilkes, M.D. is an independent director who joined our Board in June 2021 and is a member of the Compensation and Management Development Committee and the Nominating and Corporate Governance Committee. Dr. Wilkes has served as Dean Emeritus at the University of Virginia School of Medicine since 2021. Dr. Wilkes previously served as dean and as the James Carroll Flippin Professor of Medical Science at the University of Virginia School of Medicine from 2015 to 2021. Before that, he served in positions of increasing responsibility at Indiana University School of Medicine, including as the Executive Associate Dean for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder and member of the board of directors of ImmuneWorks Inc., a biotechnology start-up company, and has served as its Chief Scientific Officer since 2006. Since 2013, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. This program seeks to increase underrepresented minority physician-scientists, dentist scientists and nurse scientists at leading academic medical centers in the United States. In 2020, he was elected to the National Academy of Medicine.

Dr. Wilkes currently serves on the board of directors of Baxter International Inc. (NYSE: BAX), a leading global medical products company, where he serves on the Quality, Compliance and Technology Committee. Dr. Wilkes also serves as an advisory board member for DevPro Biopharma, LLC, a clinical research and development accelerator; Cartesian Therapeutics, Inc., a biotechnology company; and Magnolia Therapeutics, LLC. He also serves as a member of the board of trustees of Villanova University, and the board of visitors of the Lewis Katz School of Medicine at Temple University. He received his bachelor's degree in biology from Villanova University, his medical degree from Temple University School of Medicine, and conducted his residency at Temple University Hospital. Dr. Wilkes completed a post-doctoral fellowship in pulmonary and critical care at University of Texas Southwestern Medical Center. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps where he as awarded a Commendation Medal for meritorious service.

Member of the Compensation and Management Development Committee

Member of the Nominating and Corporate Governance Committee

Director

Alfonso G. Zulueta is an independent director who joined our Board in January 2022 and is a member of the Nominating and Corporate Governance Committee. Mr. Zulueta has over three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company (NYSE: LLY). At Eli Lilly, he held key senior positions including Vice President of Global Marketing, President of Global Oncology and Critical Care Products, and most recently as President of International responsible for all geographies outside the United States and Canada from 2017 until his retirement at the end of 2021. He was a corporate officer and member of Eli Lilly and Company’s executive committee.

Mr. Zulueta currently serves on the board of directors of CTS Corporation (NYSE: CTS), a global manufacturer of sensors, connectivity components, and actuators, where he serves on the Audit Committee ; Compensation Committee; and the Nominating, Governance, and Sustainability Committee. He also currently serves on the board of directors of Calidi Biotherapeutics, a clinical-stage biotechnology company and Glooko, Inc., a technology company providing personalized remote patient monitoring for diabetes and other related conditions. He also previously served on the board of directors of Amarin Corporation (Nasdaq: AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health and as a member of the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and US-Japan Business Council. He received his Bachelor of Arts in Economics from De La Salle University in the Philippines, and his MBA from Colgate Darden Graduate School of Business Administration at the University of Virginia.

Member of the Nominating and Corporate Governance Committee

Member of the Compensation and Management Development Committee